VASANTHI AVADHANULA to Respiratory Syncytial Virus Vaccines
This is a "connection" page, showing publications VASANTHI AVADHANULA has written about Respiratory Syncytial Virus Vaccines.
Connection Strength
0.855
-
Mucosal vaccines with STING-agonist liposomal formulations inhibit RSV (respiratory syncytial virus) replication in cotton rats. Vaccine. 2025 May 22; 56:127183.
Score: 0.226
-
The Efficiency of p27 Cleavage during In Vitro Respiratory Syncytial Virus (RSV) Infection Is Cell Line and RSV Subtype Dependent. J Virol. 2023 05 31; 97(5):e0025423.
Score: 0.197
-
Antibody responses of healthy adults to the p27 peptide of respiratory syncytial virus fusion protein. Vaccine. 2022 01 24; 40(3):536-543.
Score: 0.179
-
A prospective surveillance study on the kinetics of the humoral immune response to the respiratory syncytial virus fusion protein in adults in Houston, Texas. Vaccine. 2021 02 22; 39(8):1248-1256.
Score: 0.168
-
Seasonality, Clinical Characteristics, and Outcomes of Respiratory Syncytial Virus Disease by Subtype Among Children Aged <5 Years: New Vaccine Surveillance Network, United States, 2016-2020. Clin Infect Dis. 2024 05 15; 78(5):1352-1359.
Score: 0.053
-
Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B. PLoS One. 2017; 12(4):e0175792.
Score: 0.032